Taltirelin
Also known as: Ceredist, L-TRH analog, N-[(4S)-hexahydro-2,6-dioxo-4-pyrimidinylcarbonyl]-L-histidyl-L-prolinamide, TA-0910, TA‑0910, Taltirelin
Source Taltirelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Taltirelin is a synthetic, orally active analogue of thyrotropin‑releasing hormone (TRH). It is approved in Japan (trade name Ceredist) for the treatment of spinocerebellar degeneration and has been investigated in other cerebellar ataxias, experimental models of brain injury, and as a potential adjuvant to immune‑checkpoint blockade.
Mechanism of Action
Taltirelin binds to TRH receptors with roughly one‑tenth the affinity of native TRH, yet its high metabolic stability allows prolonged presence in blood and brain. This results in potent central nervous system stimulation—antagonising pentobarbital‑induced anaesthesia and reserpine‑induced hypothermia—while producing markedly weaker endocrine effects. Recent data suggest it can also raise thyroid‑stimulating hormone, which in turn activates CD8⁺ T‑cells and may augment anti‑tumour immunity.
What the Research Shows
Preclinical mouse and rat studies reported that taltirelin is about 100‑fold more potent than TRH for CNS stimulation and lasts eight times longer, with reduced endocrine activity. A Japanese clinical series of ten Machado‑Joseph disease patients showed significant improvement in acoustic speech parameters after four weeks, though overall ataxia scores (ICARS) were unchanged. A single case of spinocerebellar ataxia type 31 reported no clinical benefit. A 2024 data‑driven screen identified taltirelin as the strongest synergist with immune‑checkpoint blockade in mouse tumour models, linked to CD8⁺ T‑cell activation via TSH induction. A 2022 review highlighted animal evidence that taltirelin reverses opioid‑induced respiratory depression, but human data are lacking.
Reported Benefits
Evidence suggests taltirelin can improve ataxic speech in Machado‑Joseph disease and provides robust CNS stimulation with minimal endocrine side effects. Animal models indicate neuroprotective actions, respiratory stimulation, and a capacity to boost CD8⁺ T‑cell responses, raising the possibility of enhancing cancer immunotherapy.
Limitations of the Evidence
Clinical data are sparse: the only published human trial involved ten patients and showed no change in overall ataxia scores, and a single case report noted disease progression despite treatment. No randomized controlled trials have been reported, and human safety or efficacy for respiratory reversal or immunotherapy augmentation remains untested.
Safety Considerations
Compared with native TRH, taltirelin produces about five‑fold lower endocrine activity, reducing the risk of thyroid‑axis disturbances. However, the drug still influences the hypothalamic‑pituitary‑thyroid axis, so monitoring of thyroid function may be warranted. No specific adverse events were detailed in the abstracts, underscoring the need for further safety evaluation in larger human studies.
How It Is Administered
Taltirelin is formulated as an oral tablet (taltirelin hydrate) and administered by mouth. In research settings, intravenous infusion of TRH has been used, but taltirelin itself is primarily studied as an oral preparation.
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Cognitive impairmentNeurologyModerate
- Spinocerebellar degeneration treatmentNeurologicalModerate
- Amyotrophic lateral sclerosis (ALS) treatmentNeurologicalLow
- Motor dysfunction in Parkinsonian syndromesNeurologyModerate
- DepressionPsychiatryLow
- Cerebellar ataxia symptom reliefNeurologicalModerate
Contraindications
- HyperthyroidismEndocrineHigh
- Hypersensitivity to taltirelin or TRH analoguesAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Pituitary adenomaOncologyModerate
- Pituitary apoplexy or pituitary tumorsEndocrineHigh
Adverse Effects
- Urinary urgencyGenitourinaryUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- Increased blood pressureCardiovascularUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Elevation of thyroid-stimulating hormone (TSH)EndocrineCommon
- Hot flush / warmth sensationAutonomicCommon
Drug Interactions
- Antihypertensive agentsModerate
- LevothyroxineModerate
- CNS depressants (e.g., benzodiazepines)Low
- Thyroid hormone medications (levothyroxine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatrics (<12 y)AgeRelative
- Elderly (>75 y)AgeRelative
- Patients with cardiac diseaseCardiovascularRelative
- Elderly patientsAgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionUnapprovedNot authorized for marketing.
- JPApprovedApproved: cognitive impairment associated with neurodegenerative diseaseMarketed as a prescription drug in Japan.
- United StatesInvestigationalUnder IND for clinical trials.
- United KingdomUnapprovedNot approved by the MHRA.
Approved in Japan (marketed as Ceredist) for spinocerebellar degeneration. Not approved by the FDA or EMA. Classified as a prescription drug in Japan.
Evidence & Sources
- Journal ArticleModerateSaito R, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateKhomane KS, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleModerateYamamura M, Suzuki M, Matsumoto K1997-01-01T00:00:00.000000Z
- Journal ArticleLowXia Y, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateAlgera MH, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateShirasaki H, et al.2003-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is taltirelin officially approved to treat?
In Japan, taltirelin (Ceredist) is approved for spinocerebellar degeneration, a group of hereditary cerebellar ataxias.
Has taltirelin been shown to improve overall motor function in ataxia patients?
A small study in Machado‑Joseph disease demonstrated improved speech acoustic measures after four weeks, but the International Cooperative Ataxia Rating Scale scores did not change significantly.
Can taltirelin be used to reverse opioid‑induced respiratory depression in humans?
Animal experiments suggest it stimulates breathing, yet no human trials have evaluated taltirelin for this purpose; current evidence is limited to preclinical data.
Is taltirelin being explored for cancer therapy?
A 2024 computational‑experimental study identified taltirelin as a potent enhancer of immune‑checkpoint blockade in mouse tumour models, acting through CD8⁺ T‑cell activation mediated by thyroid‑stimulating hormone.
What are the main safety concerns with taltirelin?
While its endocrine effects are weaker than native TRH, the drug can still affect thyroid hormone regulation, so monitoring thyroid function is advisable. Detailed adverse‑event data are not available from the cited literature.
What is Taltirelin?
Taltirelin is a synthetic, orally active analogue of thyrotropin‑releasing hormone (TRH). It is approved in Japan (trade name Ceredist) for the treatment of spinocerebellar degeneration and has been investigated in other cerebellar ataxias, experimental models of brain injury, and as a potential adjuvant to immune‑checkpoint blockade.
What is Taltirelin used for?
Taltirelin is educationally associated with: Neuroprotection, Cognitive impairment, Spinocerebellar degeneration treatment, Amyotrophic lateral sclerosis (ALS) treatment, Motor dysfunction in Parkinsonian syndromes, Depression, Cerebellar ataxia symptom relief. Educational only — not medical advice.
How is Taltirelin administered?
Recorded routes of administration: Intramuscular, Intravenous, Oral, Subcutaneous.
What are the potential side effects of Taltirelin?
Reported adverse effects include: Urinary urgency, Headache, Hypotension, Increased blood pressure, Nausea, Vomiting, Elevation of thyroid-stimulating hormone (TSH), Hot flush / warmth sensation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Taltirelin?
Recorded contraindications: Hyperthyroidism, Hypersensitivity to taltirelin or TRH analogues, Pregnancy, Pituitary adenoma, Pituitary apoplexy or pituitary tumors. Consult a qualified clinician before use.